Resonium A

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Polystyrene sulfonate - sodium

Patient Information leaflet

RESONIUM A
®

_sodium polystyrene sulfonate_
CONSUMER MEDICINE INFORMATION (CMI)

WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Resonium A.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking this medicine
against the benefits they expect it
will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
Keep this leaflet with the medicine.
You may need to read it again.
WHAT RESONIUM A IS
USED FOR
Resonium A is a type of medicine
used to help remove excessive
amounts of potassium from the
blood.
Resonium A contains sodium
polystyrene sulfonate which contains
sodium atoms. This sodium is
swapped for potassium in the body,
particularly in the large intestine.
Resonium A does not enter the
bloodstream from the intestine. It is
passed (with the potassium ions) with
the faeces.
Your doctor, however, may prescribe
Resonium A for another purpose.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY IT HAS BEEN
PRESCRIBED FOR YOU.
This medicine is only available with
a doctor's prescription.
BEFORE YOU TAKE IT
_WHEN YOU MUST NOT TAKE IT_
DO NOT TAKE RESONIUM A IF YOU
HAVE:
•
a bowel obstruction
•
low levels of potassium (less than
5 mmol/L)
DO NOT TAKE RESONIUM A IF YOU ARE
ALLERGIC TO IT OR ANY OF THE
INGREDIENTS LISTED AT THE END OF THIS
LEAFLET.
Some symptoms of an allergic
reaction include skin rash, itching,
shortness of breath or swelling of the
face, lips or tongue, which may cause
difficulty in swallowing or breathing.
DO NOT GIVE ORAL RESONIUM A TO
NEWBORN BABIES.
Orally administered Resonium A has
caused bowel obstruction in
newborns. Resonium A should only
be given rectally to newborns
DO NOT TAKE IT IF YOU ARE PREGNANT
OR INTEND TO BECOME PREGNANT.
DO NOT TAKE IT IF YOU ARE
BREASTFEEDING OR PLANNING TO
BREASTFEED.
DO NOT TAKE IT AFTER THE EXPIRY DATE
(EXP) PRINTED ON THE PAC

Summary of Product characteristics

 
Resonium A PI 
#65692v3.0 
Page 1 

PRODUCT INFORMATION 
RESONIUM A

NAME OF THE MEDICINE 
NON-PROPRIETARY NAME 
Sodium polystyrene sulfonate 
CHEMICAL STRUCTURE 
CAS NUMBER 
28210-41-5 [9003-59-2] 
DESCRIPTION 
Resonium A contains 99.93% sodium polystyrene sulfonate as a finely
ground powder.  The 
sodium content is approximately 4.1mmol (100 mg) per gram of
Resonium A. 
Resonium A also contains saccharin sodium and vanillin. 
PHARMACOLOGY 
CLASS 
Sodium polystyrene sulfonate is a cation exchange resin prepared in
the sodium phase.   
SITE AND MODE OF ACTION 
It has an _in_  _vitro_ exchange capacity of approximately
3.1 mmol of potassium per gram of resin.  
However, _in_ _vivo_ the actual amount of potassium bound is
closer to 1 mmol of potassium per gram.   
PHARMACOKINETICS 
Absorption 
Sodium polystyrene sulfonate is not absorbed from the
gastrointestinal tract. 
Distribution 
Sodium polystyrene sulfonate removes potassium from the body by
exchanging it within the gut for 
sodium.   
Excretion 
For the most part, this action occurs in the large intestine, which
excretes potassium to a greater 
degree than does the small intestine.   
The efficiency of potassium exchange is unpredictable and variable. 
CH
SO
3
CH
2
CH
SO
3
CH
2
-
-
_n_
_m_
Na
+

Resonium A PI 
#65692v3.0 
Page 2 

INDICATIONS 
Treatment of hyperkalaemia. 
CONTRAINDICATIONS 
•  History of hypersensitivity to polystyrene sulfonate resins. 
•  Serum potassium levels less than 5 mmol/L 
•  Obstructive bowel disease 
•  Resonium A should not be administered ORALLY to neonates and
is contraindicated in neonates 
with reduced gut motility (eg. post-operatively or drug induced) 
PRECAUTIONS 
Serious potassium deficiency can result from Resonium A therapy.  It
is imperative to determine 
serum potassium levels at least daily and more frequently when
indicated, especially in patients on 
digoxin.  Therapy should be discontinued when serum potas